#2075
Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction:
Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Antonijoan Arbós R,
Lachamp L,
Cabello F,
Molina P,
Coimbra J,
Keywords:
Apoc,
somatostatin,
analogues,
controlled release,
octreotide,
octreotide acetate,
phase 1,
studies,
clinical trial,
study,
neuroendocrine,
tumor,
slow,
release,
formulation,
therapeutics,
injection,
drug effect,
clinical,
trial,
im,
sc,
#194
Pancreatic Neuroendocrine Tumors: Experience of Endocrinology Department of the University Hospital of Coimbra
Introduction:
Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms, comprising 1-2% of all pancreatic tumors. The majority are nonfunctional. Of the functional tumors, insulinomas are the most common.
Conference:
8th Annual ENETSConcerence (2011)
Presenting Author:
Authors:
Vieira A,
Santos J,
Gomes L,
Moreira A,
Alves M,
Keywords:
pancreatic neuroendocrine tumors,
insulinoma,
hereditary tumor syndromes,
